Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) Operating Expenses (2016 - 2025)

Kiora Pharmaceuticals' Operating Expenses history spans 11 years, with the latest figure at $7.3 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 185.03% year-over-year to $7.3 million; the TTM value through Dec 2025 reached $12.8 million, up 11.48%, while the annual FY2025 figure was $12.8 million, 11.48% up from the prior year.
  • Operating Expenses reached $7.3 million in Q4 2025 per KPRX's latest filing, up from $794437.0 in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $7.3 million in Q4 2025 to a low of $794437.0 in Q3 2025.
  • Average Operating Expenses over 5 years is $3.2 million, with a median of $2.6 million recorded in 2023.
  • Peak YoY movement for Operating Expenses: surged 439.17% in 2021, then tumbled 77.95% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $6.4 million in 2021, then crashed by 41.88% to $3.7 million in 2022, then plummeted by 42.79% to $2.1 million in 2023, then rose by 21.05% to $2.6 million in 2024, then surged by 185.03% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for KPRX's Operating Expenses are $7.3 million (Q4 2025), $794437.0 (Q3 2025), and $2.4 million (Q2 2025).